CORCEPT THERAPEUTICS INC (CORT) Fundamental Analysis & Valuation

NASDAQ:CORT • US2183521028

Current stock price

33.51 USD
+1.33 (+4.13%)
At close:
33.51 USD
0 (0%)
After Hours:

This CORT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. CORT Profitability Analysis

1.1 Basic Checks

  • CORT had positive earnings in the past year.
  • In the past year CORT had a positive cash flow from operations.
  • CORT had positive earnings in each of the past 5 years.
  • In the past 5 years CORT always reported a positive cash flow from operatings.
CORT Yearly Net Income VS EBIT VS OCF VS FCFCORT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

1.2 Ratios

  • With an excellent Return On Assets value of 11.91%, CORT belongs to the best of the industry, outperforming 92.71% of the companies in the same industry.
  • The Return On Equity of CORT (15.38%) is better than 88.54% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 5.84%, CORT belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for CORT is in line with the industry average of 12.98%.
  • The 3 year average ROIC (13.70%) for CORT is well above the current ROIC(5.84%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 11.91%
ROE 15.38%
ROIC 5.84%
ROA(3y)15.26%
ROA(5y)17.94%
ROE(3y)19.04%
ROE(5y)21.45%
ROIC(3y)13.7%
ROIC(5y)17.86%
CORT Yearly ROA, ROE, ROICCORT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

1.3 Margins

  • With an excellent Profit Margin value of 13.09%, CORT belongs to the best of the industry, outperforming 86.46% of the companies in the same industry.
  • In the last couple of years the Profit Margin of CORT has declined.
  • The Operating Margin of CORT (5.88%) is better than 79.69% of its industry peers.
  • In the last couple of years the Operating Margin of CORT has declined.
  • CORT has a Gross Margin of 98.30%. This is amongst the best in the industry. CORT outperforms 97.40% of its industry peers.
  • In the last couple of years the Gross Margin of CORT has remained more or less at the same level.
Industry RankSector Rank
OM 5.88%
PM (TTM) 13.09%
GM 98.3%
OM growth 3Y-40.56%
OM growth 5Y-30.48%
PM growth 3Y-19.65%
PM growth 5Y-15.26%
GM growth 3Y-0.12%
GM growth 5Y-0.02%
CORT Yearly Profit, Operating, Gross MarginsCORT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CORT Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CORT is still creating some value.
  • The number of shares outstanding for CORT has been increased compared to 1 year ago.
  • CORT has less shares outstanding than it did 5 years ago.
  • CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CORT Yearly Shares OutstandingCORT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
CORT Yearly Total Debt VS Total AssetsCORT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 13.50 indicates that CORT is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 13.50, CORT belongs to the top of the industry, outperforming 86.46% of the companies in the same industry.
  • CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 13.5
ROIC/WACC0.62
WACC9.38%
CORT Yearly LT Debt VS Equity VS FCFCORT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.3 Liquidity

  • CORT has a Current Ratio of 2.92. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.92, CORT is in line with its industry, outperforming 51.04% of the companies in the same industry.
  • A Quick Ratio of 2.85 indicates that CORT has no problem at all paying its short term obligations.
  • The Quick ratio of CORT (2.85) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.92
Quick Ratio 2.85
CORT Yearly Current Assets VS Current LiabilitesCORT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. CORT Growth Analysis

3.1 Past

  • CORT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.87%.
  • Measured over the past years, CORT shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.72% on average per year.
  • CORT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.79%.
  • Measured over the past years, CORT shows a quite strong growth in Revenue. The Revenue has been growing by 16.56% on average per year.
EPS 1Y (TTM)-33.87%
EPS 3Y-2.33%
EPS 5Y-0.72%
EPS Q2Q%-23.08%
Revenue 1Y (TTM)12.79%
Revenue growth 3Y23.74%
Revenue growth 5Y16.56%
Sales Q2Q%11.12%

3.2 Future

  • CORT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 59.90% yearly.
  • CORT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.39% yearly.
EPS Next Y0.76%
EPS Next 2Y65.28%
EPS Next 3Y74.95%
EPS Next 5Y59.9%
Revenue Next Year19.16%
Revenue Next 2Y24.58%
Revenue Next 3Y23.49%
Revenue Next 5Y22.39%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CORT Yearly Revenue VS EstimatesCORT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B 2.5B
CORT Yearly EPS VS EstimatesCORT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

5

4. CORT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 40.87, which means the current valuation is very expensive for CORT.
  • Compared to the rest of the industry, the Price/Earnings ratio of CORT indicates a somewhat cheap valuation: CORT is cheaper than 78.65% of the companies listed in the same industry.
  • CORT's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.11.
  • A Price/Forward Earnings ratio of 40.56 indicates a quite expensive valuation of CORT.
  • CORT's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CORT is cheaper than 71.35% of the companies in the same industry.
  • CORT is valuated expensively when we compare the Price/Forward Earnings ratio to 24.12, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 40.87
Fwd PE 40.56
CORT Price Earnings VS Forward Price EarningsCORT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • CORT's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CORT is cheaper than 75.52% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, CORT is valued cheaper than 82.81% of the companies in the same industry.
Industry RankSector Rank
P/FCF 25.14
EV/EBITDA 60.7
CORT Per share dataCORT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • CORT has an outstanding profitability rating, which may justify a higher PE ratio.
  • CORT's earnings are expected to grow with 74.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)54.05
PEG (5Y)N/A
EPS Next 2Y65.28%
EPS Next 3Y74.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CORT Dividend Analysis

5.1 Amount

  • CORT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CORT Fundamentals: All Metrics, Ratios and Statistics

CORCEPT THERAPEUTICS INC

NASDAQ:CORT (3/17/2026, 8:07:25 PM)

After market: 33.51 0 (0%)

33.51

+1.33 (+4.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners72.58%
Inst Owner Change-1.77%
Ins Owners6.64%
Ins Owner Change0.89%
Market Cap3.56B
Revenue(TTM)761.41M
Net Income(TTM)99.65M
Analysts75
Price Target85.68 (155.68%)
Short Float %13.3%
Short Ratio5.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.22%
Min EPS beat(2)-34.64%
Max EPS beat(2)16.19%
EPS beat(4)3
Avg EPS beat(4)12.54%
Min EPS beat(4)-34.64%
Max EPS beat(4)51.63%
EPS beat(8)6
Avg EPS beat(8)12.54%
EPS beat(12)9
Avg EPS beat(12)13.9%
EPS beat(16)11
Avg EPS beat(16)8.82%
Revenue beat(2)0
Avg Revenue beat(2)-14.56%
Min Revenue beat(2)-22.27%
Max Revenue beat(2)-6.85%
Revenue beat(4)0
Avg Revenue beat(4)-11.72%
Min Revenue beat(4)-22.27%
Max Revenue beat(4)-4.4%
Revenue beat(8)3
Avg Revenue beat(8)-5.96%
Revenue beat(12)6
Avg Revenue beat(12)-3.32%
Revenue beat(16)7
Avg Revenue beat(16)-3.6%
PT rev (1m)-10.83%
PT rev (3m)-37.88%
EPS NQ rev (1m)79.07%
EPS NQ rev (3m)73.33%
EPS NY rev (1m)33.52%
EPS NY rev (3m)-38.91%
Revenue NQ rev (1m)-8.11%
Revenue NQ rev (3m)-19.16%
Revenue NY rev (1m)-8.11%
Revenue NY rev (3m)-15.99%
Valuation
Industry RankSector Rank
PE 40.87
Fwd PE 40.56
P/S 4.68
P/FCF 25.14
P/OCF 25.1
P/B 5.5
P/tB 5.5
EV/EBITDA 60.7
EPS(TTM)0.82
EY2.45%
EPS(NY)0.83
Fwd EY2.47%
FCF(TTM)1.33
FCFY3.98%
OCF(TTM)1.33
OCFY3.98%
SpS7.16
BVpS6.09
TBVpS6.09
PEG (NY)54.05
PEG (5Y)N/A
Graham Number10.6
Profitability
Industry RankSector Rank
ROA 11.91%
ROE 15.38%
ROCE 6.68%
ROIC 5.84%
ROICexc 13.36%
ROICexgc 13.36%
OM 5.88%
PM (TTM) 13.09%
GM 98.3%
FCFM 18.62%
ROA(3y)15.26%
ROA(5y)17.94%
ROE(3y)19.04%
ROE(5y)21.45%
ROIC(3y)13.7%
ROIC(5y)17.86%
ROICexc(3y)38.16%
ROICexc(5y)61.97%
ROICexgc(3y)38.16%
ROICexgc(5y)61.97%
ROCE(3y)15.67%
ROCE(5y)20.43%
ROICexgc growth 3Y-52.44%
ROICexgc growth 5Y-36.96%
ROICexc growth 3Y-52.44%
ROICexc growth 5Y-36.96%
OM growth 3Y-40.56%
OM growth 5Y-30.48%
PM growth 3Y-19.65%
PM growth 5Y-15.26%
GM growth 3Y-0.12%
GM growth 5Y-0.02%
F-Score6
Asset Turnover0.91
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 18.36%
Cap/Sales 0.03%
Interest Coverage 250
Cash Conversion 309.05%
Profit Quality 142.28%
Current Ratio 2.92
Quick Ratio 2.85
Altman-Z 13.5
F-Score6
WACC9.38%
ROIC/WACC0.62
Cap/Depr(3y)101.64%
Cap/Depr(5y)80.07%
Cap/Sales(3y)0.13%
Cap/Sales(5y)0.12%
Profit Quality(3y)133.58%
Profit Quality(5y)133.55%
High Growth Momentum
Growth
EPS 1Y (TTM)-33.87%
EPS 3Y-2.33%
EPS 5Y-0.72%
EPS Q2Q%-23.08%
EPS Next Y0.76%
EPS Next 2Y65.28%
EPS Next 3Y74.95%
EPS Next 5Y59.9%
Revenue 1Y (TTM)12.79%
Revenue growth 3Y23.74%
Revenue growth 5Y16.56%
Sales Q2Q%11.12%
Revenue Next Year19.16%
Revenue Next 2Y24.58%
Revenue Next 3Y23.49%
Revenue Next 5Y22.39%
EBIT growth 1Y-67.29%
EBIT growth 3Y-26.45%
EBIT growth 5Y-18.97%
EBIT Next Year114.05%
EBIT Next 3Y69.77%
EBIT Next 5Y38.71%
FCF growth 1Y-27.71%
FCF growth 3Y5.75%
FCF growth 5Y-1.23%
OCF growth 1Y-28.39%
OCF growth 3Y5.68%
OCF growth 5Y-1.35%

CORCEPT THERAPEUTICS INC / CORT Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CORCEPT THERAPEUTICS INC (CORT) stock?

ChartMill assigns a fundamental rating of 7 / 10 to CORT.


Can you provide the valuation status for CORCEPT THERAPEUTICS INC?

ChartMill assigns a valuation rating of 5 / 10 to CORCEPT THERAPEUTICS INC (CORT). This can be considered as Fairly Valued.


Can you provide the profitability details for CORCEPT THERAPEUTICS INC?

CORCEPT THERAPEUTICS INC (CORT) has a profitability rating of 8 / 10.


What are the PE and PB ratios of CORCEPT THERAPEUTICS INC (CORT) stock?

The Price/Earnings (PE) ratio for CORCEPT THERAPEUTICS INC (CORT) is 40.87 and the Price/Book (PB) ratio is 5.5.